Fractyl has shared pivotal results for its approach to holding onto weight loss once people come off GLP-1 treatment.
Recap by typeshit. Full story at The Pharma Letter.
Weight loss may explain much of the knee benefit, but lab work hints at anti-inflammatory and cartilage effects worth a closer read.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
A SURPASS-4 analysis at ASN Kidney Week 2026 found rapid kidney decline in 5% on tirzepatide versus 13% on insulin glargine, with the biggest gains in high protein groups.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
One product appeared to come from a 'research use only' vendor called AlphaLabs. Harvard's Pieter Cohen urges the FDA to investigate; Public Citizen counts at least 14 hospitalizations.
Buchanan Ingersoll & Rooney outlines what compounding pharmacies should watch for now that the FDA has sent its interim peptide policy to the White House for review.
Loading…